Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Px-12. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN known ✓ | P10599 | 1/20 | 1.00 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 1.00 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503342 | 0.73 | TXN (0.55) | TXNTXNRD1FDPSTAAR1ALDH1A1 | |
| SCHEMBL7064359 | 0.73 | — | — | |
| SCHEMBL31202896 | 0.70 | TXN (0.54) | TXNTXNRD1FDPSTAAR1ALDH1A1 | |
| SCHEMBL2554818 | 0.69 | — | — | |
| SCHEMBL5343833 | 0.69 | — | — | |
| SCHEMBL8429867 | 0.68 | FDPS (0.57) | TXNTXNRD1FDPSTAAR1ALDH1A1 | |
| SCHEMBL5551187 | 0.68 | TXN (0.51) | TXNTXNRD1FDPSALDH1A1SMN1; SMN2 | |
| SCHEMBL24505623 | 0.67 | TXN (0.50) | TXNTXNRD1FDPSCTSZ | |
| SCHEMBL14406850 | 0.66 | RAB9A (0.50) | TXNTXNRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14406849 | 0.66 | TXN (0.63) | TXNTXNRD1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4739768-A1 | PROCESS FOR ESTABLISHING A HUMAN TESTICULAR TISSUE CULTURE SYSTEM | Paterna Biosciences Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | YALE UNIVERSITY | 2025-02-06 | — | — | US | claimed |
| WO-2025010080-A1 | PROCESS FOR ESTABLISHING A HUMAN TESTICULAR TISSUE CULTURE SYSTEM | PATERNA BIOSCIENCES INC. (US) | 2025-01-09 | — | — | WO | claimed |
| US-20250006331-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | claimed |
| US-20230414579-A1 | PHARMACEUTICALS FOR COVID19 TREATMENT | NANTCELL, INC. | 2023-12-28 | — | — | US | claimed |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| EP-2950788-A1 | COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA. | University Of Huddersfield (GB) | 2015-12-09 | — | — | EP | claimed |
| WO-2015009699-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | KETTER PATRICK (US) | 2015-01-22 | — | — | WO | claimed |
| WO-2014118578-A1 | COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA. | UNIVERSITY OF HUDDERSFIELD (GB) | 2014-08-07 | — | — | WO | claimed |
| US-8163481-B2 | Of nucleoproteins containing histones by lysis in solution comprising enzyme-inhibitory concentration of chaotropic reagent | University of Pittsburgh - of the Commonwealth Systems of Higher Education (US) | 2012-04-24 | — | — | US | claimed |
| US-20080241845-A1 | Method of Extracting Chromatin Fractions From Intact Cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-02 | — | — | US | claimed |
| EP-1786477-A2 | METHOD OF PRESELECTION PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | Prolx Pharmaceuticals Corp. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-18 | — | — | US | claimed |
| WO-2006023658-A2 | METHOD OF PRE-SELECTING PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | PROLX PHARMACEUTICALS CORP. (US) | 2006-03-02 | — | — | WO | claimed |
| WO-2005007108-A2 | ASYMMETRIC DISULFIDES AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040116496-A1 | Asymmetric Disulfides and methods of using same | PROLX PHARMACEUTICALS CORP. | 2004-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250006331-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | STAT1, STAT4, ABCB1 | TXN 4104/4885TXNRD1 3351/4885FDPS 54/4885 |
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | HIF1A, TXNRD3, HIF1AN | TXN 6/4885TXNRD1 5/4885FDPS 4290/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | TXN 18/4885TXNRD1 15/4885FDPS 2425/4885 |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | HIF1AN, HIF1A, SSB | TXN 2138/4885TXNRD1 649/4885FDPS 4498/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | TXN 4249/4885TXNRD1 3089/4885FDPS 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.